United States:
Celltrion Completes Application For FDA Approval Of CT-P41, Biosimilar Of Prolia® / Xgeva®
02 January 2024
Venable LLP
To print this article, all you need is to be registered or login on Mondaq.com.
On November 30, 2023, Celltrion announced that it filed for an abbreviated
Biologics License Application (aBLA) for FDA approval of CT-P41 (denosumab), a proposed biosimilar of Amgen's Prolia® / Xgeva®
(denosumab). There is currently another pending aBLA for a
proposed biosimilar of Prolia® / Xgeva®
from Sandoz for GP2411, which was accepted by the FDA in
February 2023. A litigation involving GP2411 was filed in May 2023 and is currently
pending. Amgen, Inc. et al v. Sandoz, Inc. et al, No. 1:23-cv-02406
(D.N.J.). No patent disputes related to Celltrion's CT-P41 have been filed yet.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
USPTO Embraces AI Tools In New Guidance
Crowell & Moring LLP
On April 11, 2024, the USPTO published its "Guidance on Use of Artificial Intelligence-Based Tools in Practice Before the United States" in the Federal Register (the "Guidance"). As the title suggests...
Breaking Down The EPO's Revised Practice Guidelines
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
The guidelines for examination in the European Patent Office instruct on the practice and procedure related to the examination of European patent applications...
USPTO Issues Guidance On Use Of AI-Based Tools
Greenberg Traurig, LLP
On April 11, 2024, the U.S. Patent and Trademark Office (USPTO) issued Guidance on Use of Artificial-Intelligence-Based Tools (Guidance), which applies existing rules and policies...